Daewoong Pharmaceutical confirms the effect of Hoystar tablet COVID-19 treatment in Phase 2a clinical trial
Daewoong Pharmaceutical’s’Hoystar tablet’ confirmed the possibility of COVID-19 treatment in phase 2a clinical trial
Ministry of Science and Technology, 5237 billion won in bio R&D including development of corona treatment and vaccine next year… 25% this year ↑